Radiopharma Allergy Immunotherapy CDMO Sterile Injectables CRDMO Generics Proprietary Novel Drugs

Proprietary Novel Drugs

Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.

Mission and Therapeutic Focus

OUR MISSION is to transform the lives of patients through the development of precision oral medicines with enhanced safety and therapeutic efficacy:

Hematology/Oncology
Solid Tumors
Immunology

From Genetic Insight to Clinical Impact

Clinical-stage precision therapeutics company founded in 2019 to discover and develop therapeutics with meaningfully improved safety and efficacy profile against first-in-class and validated but intractable targets.

Pipeline generated through in-house Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, validated through partnerships

Clinical pipeline consists of a first in class dual CoREST modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors and a novel brain-penetrant modulator of PRMT5, currently in Phase I clinical trial.

Additional pre-clinical programs include brain penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications.

Differentiated Assets in Development

The portfolio spans oncology and autoimmune mechanisms, with programs built around clear scientific and clinical rationales.

JBI-802 CoREST inhibitor in Phase II trials for heme and solid tumors; JBI-778 PRMT5 inhibitor in Phase I trials for solid tumors; PAD4 inhibitor for autoimmune disease in IND track.
FDA Orphan drug designations for JBI-802 and JBI-778

Advancing Through Clinical Development

Jubilant Therapeutics has publicly reported clinical progress in oncology for its first-in-class CoREST inhibitor program with dual LSD1/HDAC6 activity, including preliminary Phase I safety, pharmacokinetic, and initial efficacy results in thrombocytosis-linked myeloproliferative neoplasms and an expressed development opportunity in genetically defined advanced solid tumour patients.

Additional proof: The company has also announced U.S. FDA IND clearance and U.S. FDA Orphan Drug Designation for its PRMT5 inhibitor program (JBI-778), supporting its progression into clinical development in lung and brain cancers.